Curis Inc (CRIS)

Currency in USD
0.4900
-0.0052(-1.05%)
Closed·
0.4998+0.0098(+2.00%)
·
CRIS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.47840.5090
52 wk Range
0.46373.1300
Key Statistics
Prev. Close
0.4952
Open
0.4987
Day's Range
0.4784-0.509
52 wk Range
0.4637-3.13
Volume
228.03K
Average Volume (3m)
415.23K
1-Year Change
-75.3769%
Book Value / Share
0.32
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CRIS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
14.0000
Upside
+2,757.14%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Curis Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 14.0000
(+2,757.14% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jones Trading
Buy5.00+920.41%-New Coverage06/04/2026
H.C. Wainwright
Buy17.00+3,369.39%-New Coverage02/06/2025

Curis Inc Earnings Call Summary for Q1/2026

  • Q1 2026 net loss widened to $24.2M vs $10.6M prior year, driven by non-cash warrant liability adjustments from recent financing.
  • R&D expenses fell 24.7% to $6.4M reflecting cost discipline; G&A costs rose 27.5% to $5.1M year-over-year.
  • Cash runway extended into late 2027 with anticipated capital from warrant exercises; stock rose 1.8% aftermarket to $0.5609.
  • Lead candidate emavusertib remains strategic focus; lymphoma enrollment updates expected 2027, CLL data anticipated by end-2026.
  • Company faces high capital dependency on warrant exercises and clinical trial risks in competitive oncology market.
Last Updated: 12/05/2026, 22:14
Read Full Transcript

Earnings

Latest Release
12/05/2026
EPS / Forecast
-1.25 / -0.53
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Curis (CRIS) Income Statement & Profits

Compare CRIS to Peers and Sector

Metrics to compare
CRIS
Peers
Sector
Relationship
P/E Ratio
−0.9x−4.0x−0.5x
PEG Ratio
−0.01−0.130.00
Price/Book
1.5x1.0x2.6x
Price / LTM Sales
2.8x9.2x3.1x
Upside (Analyst Target)
-94.9%53.0%
Fair Value Upside
Unlock11.2%6.3%Unlock

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
519.30K1.30%247.08K
Other Institutional Investors
16.13M40.35%7.67M
Public Companies & Retail Investors
23.33M58.36%11.10M
Total
39.98M100.00%19.02M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Vanguard Index Funds - Vanguard Total Stock Market ETF0.54%215,599107
Vanguard Index Funds - Vanguard Extended Market ETF0.24%96,04348

People Also Watch

20.2100
NEGG
-1.75%
0.185
BURU
-4.63%
3.1400
KUST
-0.95%
0.390
GAME
+5.12%
3.160
AGEN
+0.32%

FAQ

What Is the Curis (NASDAQ: CRIS) Share Price Today?

The Curis stock price today is 0.4900 USD.

What Stock Exchange Does Curis (CRIS) Trade On?

Curis is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Curis?

The stock symbol (also called a 'ticker') for Curis is "CRIS."

What Is the Current Curis Market Capitalisation?

As of today, Curis (NASDAQ: CRIS) market cap is 19.7900M USD.

What Is Curis's (CRIS) Earnings Per Share (TTM)?

The Curis EPS is currently -1.3329 (Trailing Twelve Months).

When Is the Next Curis Earnings Date?

Curis's next earnings report will be released on 30/07/2026.

Is CRIS a Buy or Sell From a Technical Analyst Perspective?

Based on today's Curis moving averages and other technical indicators, the daily buy/sell signal for CRIS stock is Strong Sell.

How Many Times Has Curis Stock Split?

Curis has split 2 times. (See the CRIS stock split history page for full effective split date and price information.)

How Many Employees Does Curis Have?

Curis has 22 employees, based on their latest Companies House report.

What is the current trading status of Curis (NASDAQ: CRIS)?

As of 22/05/2026, Curis (CRIS) is trading at a share price of 0.4900 USD, with a previous close of 0.4952 USD. The stock has fluctuated within a day range of 0.4784 USD to 0.5090 USD, while its 52-week range spans from 0.4637 USD to 3.1300 USD.

What Is Curis (CRIS) Price Target According to Analysts?

The average 12-month price target for Curis is 14.0000 USD, with a high estimate of 20 USD and a low estimate of 5 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +2,757.14% Upside potential.

What Is the CRIS Premarket Price?

CRIS's last pre-market stock price is 0.5122 USD. The pre-market share volume is 240.0000, and the stock has decreased by 0.0170, or 3.4300%.

What Is the CRIS After Hours Price?

CRIS's last after hours stock price is 0.4998 USD, the stock has decreased by 0.0098, or 2.0000%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.